Our press releases
RSS feedHope, an exceptional dance gala for the benefit of research excellence
On October 21, at 8:30 p.m., the Casino de Paris will host an exceptional show for the benefit of the Institute of Myology, a research and care center of excellence created by the AFM-Telethon and dedicated to Muscle science and medicine. At the initiative of Laura Arend, dancer and choreographer, and Charlotte Ranson, dancer … [Read more]
Dr Emmanuelle Lagrue, MD-PhD, pediatric neurologist, joins Généthon and I-Motion
Dr Emmanuelle Lagrue, MD-PhD, pediatric neurologist, simultaneously joins Généthon, the AFM-Telethon laboratory dedicated to gene therapy, as Senior Medical Manager, and I-Motion, the pediatric clinical trials platform of the Institute of Myology, as Deputy Director. Holder of a university degree in pediatric neurology and a doctorate in Sciences, Dr Emmanuelle Lagrue multiplies expertises. After her pediatric … [Read more]
Experts from the Institute of Myology take the floor
Between 28 September and 2 October, the 25th International Annual Congress of the World Muscle Society, which brings together muscle experts from all over the world, will highlight the work of many researchers from the Institute of Myology, the centre of expertise on muscle and its diseases that was created by AFM-Telethon. From fundamental research … [Read more]
Martine Barkats and Maria Grazia Biferi awarded the Avi Kremer ALS Treatment Prize from Prize4Life for their gene therapy approach
Martine Barkats and Maria Grazia Biferi have received the Avi Kremer ALS Treatment Prize from Prize4Life, which is committed to the fight against Amyotrophic Lateral Sclerosis (ALS*) and awards $1 million to the winners. Within the Myology Research Centre (MRC) of the Institute of Myology, the team “CNS Gene Transfer & Biotherapy of Motor Neuron … [Read more]
YposKesi, the 1st French industrial pharmaceutical company for producing gene and cell therapy drugs for rare diseases
AFM-Téléthon and the ‘Sociétés de Projets Industriels’ SPI [Industrial Projects Companies] investment fund, managed by Bpifrance under the Programme d’Investissement d’Avenir (PIA), are creating YposKesi, the first French company to develop and produce gene and cell therapy products. This new company aims to make the first treatments available to patients and market them at a … [Read more]
